Incidence of Opioid Overdose Among Patients Using ER/LA Opioid Analgesics Before and After Implementation of the Class-Wide Opioid Risk Evaluation and Mitigation Strategy

INTRODUCTION: The United States (US) Food and Drug Administration (FDA) required a Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting (ER/LA) opioid analgesics on 09 July 2012. METHODS: This study compared the incidence of opioid overdose before (July 2010-June 2012)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Pain Res
Hauptverfasser: Esposito, Daina B, Cepeda, M Soledad, Holick, Crystal N, Knox, Caitlin, Desai, Vibha CA, Liu, Nianya, Vojjala, Shiva-Krishna, Lyons, Jennifer G, Wedin, Gregory P, Lanes, Stephan
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove 2020
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6970623/
https://ncbi.nlm.nih.gov/pubmed/32021405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JPR.S219324
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge